| Nov-09-2012 |
|
ProNAi Expands Management Team and Presents Encouraging Phase I Study Results for Lead Cancer Drug at Cancer Meeting |
| Sep-20-2010 |
|
ProNAi Initiates Phase I Cancer Clinical Study of PNT2258 |
| Mar-20-2008 |
|
ProNAi Therapeutics, Inc. Cleared to Begin Phase I Clinical Trials for the First DNA Interference (DNAi®) Therapeutic |
| Aug-23-2007 |
|
ProNAi Therapeutics Announces First DNAi® Mechanism of Action Studies for PNT2258 Oncology Drug Candidate |
| Jun-14-2007 |
|
ProNAi Names Polymun as Preferred Manufacturer of PNT2258 DNAi®-based Cancer Therapeutic |
| Apr-17-2007 |
|
ProNAi Announces Preclinical Success for PNT2258 Therapeutic – Curative Events in Xenograft Mice for Difficult-to-Treat Non-Hodgkin’s Lymphoma |
| Mar-05-2007 |
|
ProNAi and Novosom AG Announce Collaboration to Enable Delivery of DNAi®-based Cancer Therapeutics |
| Jan-08-2007 |
|
ProNAi Announces DNA Interference (DNAi®) Drug Development Strategy for 2007 |
| Oct-24-2006 |
|
ProNAi Closes Successful Bridge Funding Round, Secures $6.65 Million Total |
| Oct-12-2006 |
|
ProNAi Announces New Scientific Advisory Board |
| Sep-26-2006 |
|
ProNAi Announces Executive Team Buildup, Names New CEO and Top Development Management |
| Sep-12-2006 |
|
ProNAi Wins $3.3 Million Funding from Michigan Economic Development Corporation |
| Oct-19-2005 |
|
ProNAi Therapeutics Raises $4.25m to Develop a New Class of Therapies That Target DNA |
| |
|
|
